
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SYN-020
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Recipient : Theriva Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SYN-020 is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Radiation Enteritis.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
September 16, 2021
Lead Product(s) : SYN-020
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Recipient : Theriva Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SYN-020
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Recipient : Theriva Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics, Safety, and Tolerability of SYN-020
Details : SYN-020 is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Radiation Enteritis.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
March 25, 2021
Lead Product(s) : SYN-020
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Recipient : Theriva Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Bemotrizinol
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Royal DSM
Deal Size : Inapplicable
Deal Type : Inapplicable
Bemotrizinol UV Filter Part 1 Clinical PK Evaluation in Topical MUsT Study
Details : Bemotrizinol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 21, 2020
Lead Product(s) : Bemotrizinol
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Royal DSM
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : RZL-012
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Recipient : Raziel Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RZL-012 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 31, 2017
Lead Product(s) : RZL-012
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Recipient : Raziel Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : NYX-2925
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Aptinyx
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Tolerability, PK of Oral NYX-2925 in Healthy Volunteers
Details : NYX-2925 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 15, 2016
Lead Product(s) : NYX-2925
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Aptinyx
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Berdazimer Sodium
Therapeutic Area : Dermatology
Study Phase : Phase I
Recipient : Novan
Deal Size : Inapplicable
Deal Type : Inapplicable
A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204
Details : SB204 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Acne Vulgaris.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 20, 2015
Lead Product(s) : Berdazimer Sodium
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Recipient : Novan
Deal Size : Inapplicable
Deal Type : Inapplicable
